MedTrace Logo

Clinical Trial on the Reduction of Methicillin Resistant Staphylococcus Aureus (MRSA)

NCT00790608 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2011-11-29

No results posted yet for this study

Summary

The purpose of the study is to determine if topically applied nitric oxide gas is effective in reducing the quantity of bacteria (including MRSA)in a wound.

Conditions

  • Skin Ulcers
  • Methicillin-resistant Staphylococcus Aureus Infection

Interventions

DRUG

Nitric Oxide

Gaseous nitric oxide (1%), delivered for 30 minutes per day for 3 consecutive days

Sponsors & Collaborators

  • Nitric BioTherapeutics, Inc

    lead INDUSTRY

Principal Investigators

  • Keith Harding, MB ChB, MRGCP, FRCS · Department of Wound Healing, Cardiff University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-05-31
Completion
2011-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00790608 on ClinicalTrials.gov